Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study

NCT05811000 is registered in ClinicalTrials.gov with Mediforum Ltd., Co. as lead sponsor.

NCT NCT05811000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05811000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study
Lead sponsor
Mediforum Ltd., Co.
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 27, 2020
Completion date
August 13, 2024
Enrollment
312 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild alzheimer disease